What one share of TriSalus Life Sciences holds
We are a growing, oncology focused medical technology business seeking to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies, and with our investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 ("TRL9") agonist, for a range of different therapeutic and technology applications.
TriSalus Life Sciences’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.90 |
|---|---|
| Profit | −$1.15 |
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$0.47 |
| Cash and investments | $0.75 |
| Debt | $0.54 |
| Book value | $0.11 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2022 | $40.04 | −$161.55 | $2.12 | −$106.48 | — | −$509.11 |
| 2023 | $1.97 | −$6.77 | $0.06 | −$5.45 | — | — |
| 2024 | $1.16 | −$1.31 | $0.01 | −$1.63 | — | −$0.83 |
| 2025 | $1.19 | −$1.84 | $0.02 | −$0.50 | — | −$0.68 |
Common questions about TriSalus Life Sciences
How much does one share of TriSalus Life Sciences earn?
Over the last 12 months, TriSalus Life Sciences lost $1.15 for each share on $0.90 of sales.
Does TriSalus Life Sciences pay a dividend?
TriSalus Life Sciences didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is TriSalus Life Sciences’s book value per share?
TriSalus Life Sciences’s book value is $0.11 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of TriSalus Life Sciences have?
Each share of TriSalus Life Sciences has $0.75 of cash and investments and $0.54 of debt, as of June 30, 2026.
What is TriSalus Life Sciences’s free cash flow per share?
−$0.47 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has TriSalus Life Sciences bought back shares?
TriSalus Life Sciences’s share count rose about 12141% from 2022 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.